Weight and Muscle Mass Outcomes With Elinzanetant

Video content above is prompted by the following:

The OASIS-3 subanalysis revealed favorable body composition changes with elinzanetant treatment, including weight decrease and reduced fat mass index. These findings are particularly significant given that postmenopausal women typically experience weight gain and increased fat accumulation, making these outcomes clinically relevant for patient quality of life.

Simultaneously, elinzanetant treatment was associated with increased lean mass index, suggesting preservation or enhancement of muscle mass. This combination of decreased fat mass and increased lean mass represents an ideal body composition profile that can contribute to overall metabolic health and bone strength.

The weight-neutral or weight-reducing effects of elinzanetant, combined with favorable muscle mass changes, make this treatment particularly attractive for postmenopausal women. These body composition benefits, alongside vasomotor symptom relief and potential bone health advantages, position elinzanetant as a comprehensive therapeutic option addressing multiple aspects of menopausal health management.